Top Markets
Coin of the day
Hemostemix Inc. Hemostemix Inc.

Hemostemix Inc.

HEM
Classement en actions #32158
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Prix de l'action
$0.05504527
Dernière synchronisation: 2026-08-17
Capitalisation boursière
$10.89M
Changement (1 jour)
15.38%
Changement (1 an)
-10.64%
Pays
CA
Échange Hemostemix Inc. (HEM)

Catégorie

Historique du rendement du dividende pour Hemostemix Inc. (HEM)
Le rendement du dividende (TTM) de Hemostemix Inc. (symbole boursier : HEM) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Hemostemix Inc. (HEM) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes